784 related articles for article (PubMed ID: 33893689)
1. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
2. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.
Zhang W; Yan C; Zhang T; Chen X; Dong J; Zhao J; Han D; Wang J; Zhao G; Cao F; Zhou D; Jiang H; Tang P; Zhao L; Yuan Z; Wang Q; Wang P; Pang Q
Oncoimmunology; 2021; 10(1):1971418. PubMed ID: 34616588
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.
Guo Z; Zhang K; Wei X; Li Y; Ma X; Li Y; Han D; Du Q; Zhang T; Chen X; Wei H; Yan C; Zhang W; Pang Q; Wang P
J Leukoc Biol; 2023 Jan; 113(1):11-17. PubMed ID: 36822161
[TBL] [Abstract][Full Text] [Related]
6. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
7. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
8. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
Yan C; Huang H; Zheng Z; Ma X; Zhao G; Zhang T; Chen X; Cao F; Wei H; Dong J; Tang P; Jiang H; Wang M; Wang P; Pang Q; Zhang W
Front Immunol; 2023; 14():1138054. PubMed ID: 37275884
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
10. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
[TBL] [Abstract][Full Text] [Related]
12. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
[TBL] [Abstract][Full Text] [Related]
15. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
17. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
Yang Y; Zhu L; Cheng Y; Liu Z; Cai X; Shao J; Zhang M; Liu J; Sun Y; Li Y; Yi J; Yu B; Jiang H; Chen H; Yang H; Tan L; Li Z
BMC Cancer; 2022 May; 22(1):506. PubMed ID: 35524205
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study.
Qu Y; Munire A; Zhou N; Saifuding K; Bulibu J; Wang W; Tang X; Li N; Li J; Wang P; Tang Y
J Gastrointest Oncol; 2024 Feb; 15(1):1-11. PubMed ID: 38482217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]